Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Anaplastic Thyroid Cancer
NCT02688608Phase 2Completed
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in anaplastic thyroid cancer (ATC). Started Oct 2016; status: completed.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT02688608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688608.